The biotech IPO train is rolling onward, with five more companies climbing aboard. The companies, ranging from a late-stage firm looking to finance Phase 3 studies to preclinical companies laying the groundwork for their first drug trials with human subjects, submitted their paperwork to the SEC late Friday—just before the start of Memorial Day weekend.
Here’s a look at these aspiring public companies, their programs, and their plans for the IPO cash.
—Akero Therapeutics set a preliminary $86.2 million target for its IPO. The South San Francisco company is among the growing number of biotechs developing drugs to treat… Read more »
UNDERWRITERS AND PARTNERS